Underlying pathways include NF-κB signaling and programmed cell death ligand (PD-L1)-related and macrophage-induced immune suppression pathways, which are probably the main reasons for the low success rates obtained with novel immune checkpoint interfering therapies in glioma patients [66]. This evidence concerns the gene NFKB1 and central nervous system cancer.